Perrigo Company plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Perrigo Company plc on March 16, 2017, regarding events occurring on March 14, 2017. The filing details the entry into material definitive agreements involving amendments to the Company's existing credit facilities.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, or total debt. The document focuses exclusively on covenant modifications and leverage ratio thresholds rather than reporting period financial performance.
Material Changes and Agreements
On March 14, 2017, the Company entered into Amendment No. 4 to both its Revolving Credit Agreement and Term Loan Credit Agreement. Key modifications include:
- Reporting Deadlines: Extended the deadline for delivering annual audited financial statements for the fiscal year ending December 31, 2016, to the earlier of 180 days after year-end or 90 days after a notice of default. Quarterly financial statements for the quarter ending March 31, 2017, are now due 90 days after the quarter end.
- Asset Sale Covenant: Modified to permit the sale of Tysabri and related assets without conditions or tests, pursuant to a prior Asset Purchase Agreement involving Elan Pharma and Biogen Idec.
- Leverage Ratio Adjustments:
- For the quarter ending March 31, 2017, the maximum leverage ratio is increased to 6.0 to 1.0 if the Tysabri Sale occurs by the last day of the quarter.
- For the quarter ending June 30, 2017, the maximum leverage ratio is increased to 6.0 to 1.0 if the Tysabri Sale has occurred and the Form 10-Q is not filed by May 16, 2017.
Outlook, Risks, and Contingencies
The amendments are contingent upon the completion of the Tysabri Sale. The filing indicates that the Company is managing potential timing delays in financial reporting and asset divestiture by securing flexibility in its debt covenants. No other risks or unusual items are disclosed in this specific report.
Investor Verification Checklist
- Verify the status and expected closing date of the Tysabri asset sale to Biogen Idec.
- Confirm the Company's actual leverage ratio relative to the new 6.0 to 1.0 threshold.
- Monitor the filing date of the Form 10-Q for the quarter ended March 31, 2017, to ensure compliance with the May 16, 2017 deadline referenced in the leverage covenant.
- Review the full text of Amendment No. 4 (Exhibits 10.1 and 10.2) for additional covenants not summarized in the 8-K.